Asthma
Conditions
Brief summary
To evaluate the efficacy of SC injections of 3 regimens of adalimumab vs. placebo in the change in post-bronchodilator FEV1 from Baseline to Week 16 when used in the treatment of refractory asthma.
Interventions
Sponsors
Abbott
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Documented history of refractory asthma, as defined by the American Thoracic Society,31 defined as 1 major and at least 2 minor criteria * Actual or documented history of reversible airway obstruction * Baseline FEV1 of 40% - 80% of the predicted for height, age, and sex at Screening, as demonstrated 6 or more hours after a short-acting -agonist and/or 24 or more hours after a long-acting -agonist * History of at least 1 asthma exacerbation leading to oral, IV or IM corticosteroid or ER/Urgent Care Center visit or hospitalization within the past year prior to Screening. This asthma exacerbation should not have been within 30 days prior to Screening * Adequate cardiac, renal and hepatic function as determined by the principal investigator and demonstrated by Screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits * Subjects must be able to self-inject study medication or have a designee or healthcare professional who can inject the study medication
Exclusion criteria
* Active lung diseases (e.g., bronchitis, chronic obstructive pulmonary disease \[COPD\], interstitial lung disease, pulmonary fibrosis) other than asthma * Current treatment for corticosteroid-resistant asthma (e.g., methotrexate \[MTX\], cyclosporine, gold salts, troleandomycin, immune globulin intravenous \[IGIV\], mycophenolate mofetil) * History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma - in-situ of the cervix. * History of listeria, human immunodeficiency virus (HIV), chronic or active Hepatitis B, an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease or active TB * Females who are pregnant or will not discontinue breast-feeding. * Subject with a history of clinically significant drug or alcohol abuse in the last year * Subjects with a poorly controlled medical condition. * Abnormal, clinically significant screening laboratory and other analyses (including ECG). * Subjects with any prior exposure to Tysabri® (natalizumab) * Prior treatment with any TNF antagonist, including adalimumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint is the change from Baseline in post-bronchodilator FEV1 in subjects treated with adalimumab vs. placebo. | Week 16 |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of subjects with at least one asthma exacerbation from Baseline to the end of the double-blind period | Week 16 |
| Changes from Baseline in post-bronchodilator FEV1 | Time points other thanWeek 16 |
| Change from Baseline in pre-bronchodilator FEV1 | — |
| Change from Baseline (pre-bronchodilator) in FEV1 | 30 minutes postbronchodilator |
| Change from Baseline in percent predicted FEV1 | — |
Outcome results
None listed